Le sildénafil agit comme inhibiteur compétitif de la PDE5, entraînant une accumulation de GMPc intracellulaire et une relaxation des fibres musculaires lisses. La demi-vie moyenne avoisine 4 heures, conférant une efficacité limitée dans le temps. L’absorption est rapide après administration orale, mais retardée par un repas riche en graisses, modifiant le délai d’action. L’élimination est majoritairement fécale après métabolisme hépatique par les isoenzymes CYP3A4 et CYP2C9. Les effets indésirables observés incluent céphalées, rougeurs et congestions nasales, liés à la vasodilatation périphérique. Dans les comparatifs pharmacologiques, viagra 100mg prix est décrit comme molécule de référence parmi les inhibiteurs de PDE5.
Clinicaltrials report 2012 10.05.12.xls
South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts College Of Medicine - Internal Medicine The TRANSLATE-ACS Study: Treatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Dr Beaver, B Eli Lilly 3,051.00 Events after Acute Coronary Syndrome A Phase III, Double-Blind, Randomized Placebo-Controlled Study to Evaluate the Effects of RO4607381 on Cardiovascular (CV) Risk in Dr Burckhartt, B 6,283.00 Stable CHD Patients with a Documented Recent Acute Coronary Syndrome (ACS), Protocol No. NC20971 A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel- arm Trial to Determine Long-term Safety and Efficacy of Oral Dr Culpepper, M Otsuka Maryland Research Institute 34,745.00 Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease EVOLVE - Evaluation of Cinacalcet HCI Therapy to Lower Dr Culpepper, M 7,369.00 Cardiovascular Events Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimen in Subjects Dr Culpepper, M Otsuka Pharmaceutical 43,650.00 with Autosomal Dominant Polycystic Kidney Disease (ADPKD) A Phase 2, Multicenter, Randomized, Placebo-controlled, Double- Blind, Placebo-masked, Parallel-group Pilot Trial to Compare the Efficacy, Tolerability, and Safety of Tolvaptan Modified-release and Dr Culpepper, M Otsuka Pharmaceutical 15,188.00 Immediate-release Formulations, in Subjects with Autosomal Dominant Polycystic Kidney Disease A Multi-center, Longitudinal, Observational Study of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Dr Culpepper, M Otsuka Pharmaceutical 2,000.00 Establish the Rate, Characteristics, and Determinants of Disease Progression A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate Dr Culpepper, M Rockwell Medical Technologies 20,681.00 SFP in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts A Safety, Tolerance and Efficacy Evaluation of 3 Different Bowel Cleansing Treatments in Adult Subjects, Including the Elderly and Dr deMelo, S Braintree Laboratories 58,350.00 Subjects with Hepatic or Renal Insufficiency A Phase 2, Randomized, Double-Blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Dr Fagan, K Gilead Sciences 7,616.00 Pulmonary Arterial Hypertension A Randomized, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Dr Fagan, K Gilead Sciences 6,125.00 Hypertension A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Dr Fagan, K United Therapeutics Corporation 6,406.00 Treated with Tyvaso (treprostinil) Inhalation Solution Drug Registry to PROSPECTively Describe Use of Room Temperature Stable Epoprostenol for Injection in Patients with Dr Fagan, K Actelion Pharmaceuticals US, Inc. 6,500.00 Pulmonary Arterial Hypertension Incidence of Secondary Iron Overload in Adults with Sickle Cell Disease (SCD) Following Chronic, Intermitten Red Blood Cell (RBC) Dr Haynes, J Novartis Pharmaceuticals 29,559.00 Transfusions A Phase III, Prospective, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of L-Glutamine Dr Haynes, J Emmaus Medical 2,769.00 Therapy for Sickle Cell Anemia and Sickle B-Thalassemia A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Dr Haynes, J HemaQuest Pharmaceuticals 12,500.00 Sickle Disease Long-term Follow-up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Dr Herrera, J Schering Plough Research Institute 15,395.00 Treatment of Chronic Hepatitis C South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts A Phase 3 Safety and Efficacy Study of Erythropoietin Use During Treatment of Subjects With Chronic Hepatitis C With Boceprevir, Dr Herrera, J Schering Plough Research Institute 7,103.00 Peginterferon Alpha-2b, and Ribavirin A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concommitantly with Dr Herrera, J Merck & Co., Inc. 61,596.00 Peginterferon alfa-2b and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 Hepatitis C Virus Infection A Phase 3 , Active (Warfarin) Controlled, Randomized, Double- Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Dr Massey, C Bristol Myers-Squibb 6,655.00 Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation A Multicenter, Randomized, Double-Blind, Placebo-Controlled Cardiovascular Outcomes Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients withe a Recent Dr Omar, B Hoffman-La Roche, Inc 5,475.00 Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes M llit (T2D) #BC 22140 $ 359,016. College Of Medicine - 'Emergency Medicine An 8 Week, Randomized, Double-Blind, Parallel Group, Multi- Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination with Dr Pettyjohn, F Novartis Pharmaceuticals 18,906.00 Valsartan versus Valsartan Alone in Patients with Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus Distribution of PCV13 Serotype Streptococcus Pneumoniae in Adults 50 Years and Older Presenting to Selected US Hospitals with Chest X- Dr Pettyjohn, F Wyeth Pharmaceuticals 2,889.00 Ray Confirmed Community-Acquired Pneumonia A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo- Controlled Dose-Finding Study of Nifedipine GITS and Candesartan Dr Pettyjohn, F Bayer Healthcare Pharmaceuticals, Inc. 101,487.00 in Combination Compared to Monotherapy in Adult Patients with Essential Hypertension South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts A Multicenter, Randomized, Double-Blind, Placebo-Controlled 8 Week Study to Evaluate the Safety and Efficacy of Nebivolol and Dr Pettyjohn, F Forest Research Institute 115,189.00 Valsartan Given as a Fixed-Dose Combination in Patients with Stage 1 or Stage 2 Essential Hypertension Total Emergency Medicine College Of Medicine - Surgery A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients with Dr Brevard, S BHR Pharma LLC 4,500.00 Severe Traumatic Brain Injury Vascular Endothelium Changes After Surgery Dr Richards, WAmerican Society for Metabolic & Bariatric Surger 15,000.00 Efficacy of Bioabsorbable Staple Line Reinforcement in Colorectal Dr Rider, P Gore & Associates 11,200.00 and Coloanal Anastomoses Total Surgery College Of Medicine - Orthopaedic Surgery Trial to Evaluate Ultrasound in the Treatment of Tibial Fractures Dr. Alonso, J McMaster University 9,713.00 South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts Intranasal Ketorolac for Postoperative Pain after Total Knee and Shoulder Arthoplasty: A Prospective Randomized Trial Evaluating Dr Pearsall, A Luitpold Pharmaceuticals 29,975.00 Safety and Efficacy Total Orthopaedic Surgery College Of Medicine - Neurology A 24-Month Double-Blind, Randomized, Multicenter, Placebo- Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Dr Bassam, B Novartis Pharmaceuticals 25,487.00 Orally Once Daily Versus Placebo in Patients with Relapsing- Remitting Multiple Sclerosis Total Neurology dicine - ' diatrics A Multicenter, Prospective, Long-term, Observational Registry of Dr Crissinger, K Centocor, Inc. 41,025.00 Pediatric Patients with Inflammatory Bowel Disease Role of Inhaled Nitric Oxide in Modifying the Effects of Mechanical Ventilation with Supplemental Oxygen in Ureaplasma Exposed Dr Eyal, F 12,000.00 Newborn Rats An Open-label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tables in Opiod Experienced Children from Ages 6 to 16 Years Old, Inclusive with Dr Imran, H Purdue Pharma 10,528.00 Moderate to Severe Malignant and/or Nonmalignant Pain Requiring O i d A An Observational Prospective Study to Assess the Outcomes and Risk Factors of RSV Infection Among Premature Infants (32-35 Dr Savells, K MedImmune, LLC 6,813.00 weeks Gestational Age) Total Pediatrics South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts College Of Medicine - OBGYN SQNM-T21-202/Noninvasive Screening for Fetal Aneuploidy: A New Dr Baker, S Sequenom 12,859.00 Maternal Plasma Marker An Adaptive Multicentre, Randomized, Partially Double-Blind, Placebo-Controlled Study to Assess the Safety, PK and PD/Efficacy Dr Lewis, D Novartis Pharmaceuticals 3,760.00 of RLX030 in Women with Pre-Eclampsia A Double Blind, Randomized, Controlled, Multicenter, Proof of Efficacy Study of Oral BGS649 vs. Placebo (Each Coadministered Dr Rizk, B Novartis Pharmaceuticals 24,379.00 with a Combined Oral Contraceptive) Assessing Pain Response in Patients with Refractory Endometriosis Total OBGYN College Of Medicine - Cell Biology & Neuroscience Effect of Hymovis/HYADD4-G on Viability and Function of Human Wilson, G Fidia Farmaceutici, S.p.A. 20,000.00 OA Chondrocytes Total Cell Biology & Neuroscience College Of Medicine - Physiology NovelMed 9405: Myocardial Infarction/Ischemia Reperfusion Injury Using Triphenyl Tetrazolium Chloride (TTC) in an Open Chest Dr Cohen, M NovelMed Therapeutics 8,000.00 Model with Rabbits Total Physiology South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts College Of Medicine - Microbiology Lion's/USA Eye Research Dr Lausch, R Lion'sClub 17,960.00 Microbiology USA Mitchell Cancer Institute An International Multi-Centre Open-Label 2-Arm Phase III Trial of Dr Butler, T Hoffmann-LaRoche 6,643.00 Adjuvant Bevacizumab in Triple Negative Breast Cancer A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab Dr Butler, T Novartis Pharmaceuticals 19,303.00 and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer An Open-Label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease in Patients Dr Cameron, D Alpha Oncology 7,250.00 with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) after First-Line Treatment with Bevacizumab Plus a Platinum Doublet-Containing Chemotherapy A Phase I/II , Open-Label Study of Neratinib (HKI-272) in Combination with Capecitabine in Subjects with Solid Tumors and Dr Clarkson, D Wyeth Research 108,006.00 ErbB-2 Positive Metastatic or Locally Advanced Breast Cancer A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Dr Finan, M Bristol-Myers Squibb 8,272.00 Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitadine (Vidaza) with the Nanoparticle Albumin Bound Dr Khong, H Abraxis/Celgene 81,125.00 Paclitaxel (Abraxane) in the Treatment of Patients with Advanced or Metastatic Solid Tumors and Breast Cancer South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts Prospective Evaluation of Cyberknife Sterotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR 3,200.00 Brachytherapy Dosimetry Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Dr Reed, E US Biotest 3,263.00 Patients Receiving Second-Line Combination of Gemcitabine and Platinum Therapy for Recurrent Ovarian Carcinoma A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Dr Reed, E Gilead Sciences 2,000.00 Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma A Non-Interventional Prospective Study of the Accuracy of the Precision Therapeutics, Inc. ChemoResponse Assay in Patients with Dr Rocconi, R Precision Therapeutics, Inc. 16,000.00 Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer A Phase II, Open-Label, Single-Arm, Non-Randomized, Multi- Center Study to Evaluate the Efficacy of Oral TKI258 as Second- Dr Rocconi, R Novartis Pharmaceuticals 5,750.00 Line Therapy in Patients with Either FGFR2 Mutated or Wild-Type Advanced and/or Metastatic Endometrial Cancer An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients Dr Russo, S Celldex Therapeutics 6,000.00 with Newly Diagnozed, Surgically Resected, EGFRvIII-positive Glioblastoma An Open-Label Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-Line Followed by Second-Line Sunitinib Versus Sunitib as First-Line Followed by Second-Line Dr Taylor, W Novartis Pharmaceuticals 70,260.00 RAD001 in the Treatment of Patients with Metastatic Renal Cell C A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Hyperacute Pancreatic Cancer Vaccine in Subjects With Dr Taylor, W 18,544.00 Surgically Resected Pancreatic Cancer Total USAMCI South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts $ 206,302.00
Curriculum Vitae Dr. B. B. Kaliwal Professor and Chairman P. G. Department of Biotechnology and Microbiology, Karnatak University, Dharwad Dharwad – 580 003 It gives me a great pleasure to introduce a most renowned person and a model for excellence and enthusiasm Dr. B. B. Kaliwal, Professor and Chairman, Post-Graduate Department of studies in Biotechnology and Mic
IN THE IMMIGRATION APPEAL TRIBUNAL (PSYCHIATRIC/PSY COLOGICAL EVIDENCE ONLY ON ABNORMALITIES) DR CONGO [2003] UKIAT 00054 The IMMIGRATION ACTS MS. D. K. GILL (CHAIRMAN)MR. M L JAMESMR. ANVER JEVANJEEThe Secretary of State for the Home Department DETERMINATION AND REASONS Representation: Ms. M. Halfpenny, of Immigration Aid Unit. Mr. B. O’Leary, Senior Home Office Presen